Medicus Pharma (NASDAQ:MDCX) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen downgraded shares of Medicus Pharma (NASDAQ:MDCX) from a sell rating to a strong sell rating in a research report released on Sunday morning,Wall Street Zen reports.

MDCX has been the subject of a number of other research reports. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a report on Monday, September 14th. Weiss Ratings raised Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $450.00.

Medicus Pharma Stock Performance

MDCX stock opened at $1.87 on Friday. Medicus Pharma has a fifty-two week low of $1.70 and a fifty-two week high of $127.50. The company has a market capitalization of $2.36 million, a price-to-earnings ratio of -0.02 and a beta of 0.80. The business’s 50 day moving average price is $6.14 and its two-hundred day moving average price is $21.72.

Medicus Pharma (NASDAQ:MDCX) last released its earnings results on Friday, November 6th. The company reported ($11.64) EPS for the quarter, missing analysts’ consensus estimates of ($6.68) by ($4.96). Sell-side analysts forecast that Medicus Pharma will post -36.25 earnings per share for the current year.

Institutional Investors Weigh In On Medicus Pharma

A number of large investors have recently added to or reduced their stakes in the stock. Interchange Capital Partners LLC raised its stake in Medicus Pharma by 33.9% during the 3rd quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock valued at $343,000 after buying an additional 538,039 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Medicus Pharma by 36.8% during the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after buying an additional 64,560 shares during the period. Finally, Sterling Investment Advisors Ltd. purchased a new position in shares of Medicus Pharma in the 2nd quarter worth $45,000.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.